{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:44:13Z","timestamp":1792086253052,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225724\/Z\/22\/Z"],"award-info":[{"award-number":["225724\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTRNBC-2022\/100001, CTRQQR-2021\\100010"],"award-info":[{"award-number":["CTRNBC-2022\/100001, CTRQQR-2021\\100010"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Checkpoint inhibitor immunotherapy (CPI) for\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutant advanced melanoma first-line results in a better long-term survival compared to targeted therapy (TT), however TT induction may benefit poor prognosis groups. The parallel-arm, randomised phase II, multicentre, feasibility CAcTUS trial (Clinicaltrials.gov NCT03808441) randomised 21 patients to receive standard of care investigators choice TT or CPI, switching to the alternative upon progression (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910), or commencing TT and switching to CPI upon an \u226580% reduction of\n                    <jats:italic>BRAF<\/jats:italic>\n                    variant allele frequency\n                    <jats:italic>(<\/jats:italic>\n                    VAF) in circulating tumour DNA (ctDNA; n\u2009=\u200911). The study achieved its primary endpoints with 100% (95% confidence interval [CI]: 94-100%) of critical results provided within 7 days to inform a decision to switch and 100% of patients commencing TT achieving an \u226580% reduction of\n                    <jats:italic>BRAF<\/jats:italic>\n                    VAF (95% CI: 80-100%). Secondary outcomes included progression-free survival and overall survival. No new safety signals were observed for TT\/CPI. Post-hoc analysis of clinical features, circulating cytokines and chemokines at ctDNA nadir following TT induction suggested a more favourable profile prior to CPI initiation. Longitudinal ctDNA dynamics revealed ctDNA provided an early signal of CPI benefit and that rechallenge with TT following CPI progression resulted in a further ctDNA response. These data support the utility of ctDNA to guide treatment decision-making within a clinically relevant timeframe to optimise treatment scheduling strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-72735-8","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:14:00Z","timestamp":1779362040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-2009","authenticated-orcid":false,"given":"Rebecca J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8757-3893","authenticated-orcid":false,"given":"Dominic G.","family":"Rothwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shien","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7247-0667","authenticated-orcid":false,"given":"Juan","family":"Delgado-SanMartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-9006","authenticated-orcid":false,"given":"Yvonne","family":"Sylvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Gremel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Hockenhull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Kelso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Summersgill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-136X","authenticated-orcid":false,"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7043-0514","authenticated-orcid":false,"given":"Florent","family":"Mouliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7484-4183","authenticated-orcid":false,"given":"Richard","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1726-8850","authenticated-orcid":false,"given":"Caroline","family":"Dive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"72735_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok, J. D. et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 392, 11\u201322 (2025).","journal-title":"N. Engl. J. Med."},{"key":"72735_CR2","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.1200\/JCO.2021.39.15_suppl.9507","volume":"39","author":"R Dummer","year":"2021","unstructured":"Dummer, R. et al. Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. J. Clin. Oncol. 39, 9507 (2021).","journal-title":"J. Clin. Oncol."},{"key":"72735_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N. Engl. J. Med. 381, 626\u2013636 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72735_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins, M. B. et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: The DREAMseq trial\u2014ECOG-ACRIN EA6134. J. Clin. Oncol. 41, 186\u2013197 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72735_CR5","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan, S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma. Sci. Transl. Med. 7, 279ra41 (2015).","journal-title":"Sci. Transl. Med."},{"key":"72735_CR6","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","volume":"70","author":"A Boni","year":"2010","unstructured":"Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 70, 5213\u20135219 (2010).","journal-title":"Cancer Res"},{"key":"72735_CR7","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","volume":"18","author":"JS Khalili","year":"2012","unstructured":"Khalili, J. S. et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin. Cancer Res. 18, 5329\u20135340 (2012).","journal-title":"Clin. Cancer Res."},{"key":"72735_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","volume":"2","author":"L Haas","year":"2021","unstructured":"Haas, L. et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat. Cancer 2, 693\u2013708 (2021).","journal-title":"Nat. Cancer"},{"key":"72735_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto, P. A. et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J. Clin. Oncol. 41, 212\u2013221 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72735_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(25)00133-0","volume":"26","author":"C Robert","year":"2025","unstructured":"Robert, C. et al. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. Lancet Oncol. 26, 781\u2013794 (2025).","journal-title":"Lancet Oncol."},{"key":"72735_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee, R. J. et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann. Oncol. 29, 490\u2013496 (2018).","journal-title":"Ann. Oncol."},{"key":"72735_CR12","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan, L. et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann. Oncol. 30, 804\u2013814 (2019).","journal-title":"Ann. Oncol."},{"key":"72735_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","volume":"6","author":"MR Girotti","year":"2016","unstructured":"Girotti, M. R. et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 6, 286\u2013299 (2016).","journal-title":"Cancer Discov."},{"key":"72735_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11912-021-01151-6","volume":"24","author":"A Tivey","year":"2022","unstructured":"Tivey, A. et al. Circulating tumour DNA in melanoma\u2014clinic ready? Curr. Oncol. Rep. 24, 363\u2013373 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"72735_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/annonc\/mdw278","volume":"27","author":"G Gremel","year":"2016","unstructured":"Gremel, G. et al. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. Ann. Oncol. 27, 1959\u20131965 (2016).","journal-title":"Ann. Oncol."},{"key":"72735_CR16","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41416-022-01766-x","volume":"126","author":"VG Woof","year":"2022","unstructured":"Woof, V. G., Lee, R. J., Lorigan, P. & French, D. P. Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma. Br. J. Cancer 126, 1450\u20131456 (2022).","journal-title":"Br. J. Cancer"},{"key":"72735_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","volume":"22","author":"A Santiago-Walker","year":"2016","unstructured":"Santiago-Walker, A. et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin. Cancer Res. 22, 567\u2013574 (2016).","journal-title":"Clin. Cancer Res."},{"key":"72735_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"72735_CR19","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.1200\/JCO.2017.35.15_suppl.9546","volume":"35","author":"JHJ Lee","year":"2017","unstructured":"Lee, J. H. J. et al. Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM). J. Clin. Oncol. 35, 9546 (2017).","journal-title":"J. Clin. Oncol."},{"key":"72735_CR20","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray, E. S. et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6, 42008\u201342018 (2015).","journal-title":"Oncotarget"},{"key":"72735_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(20)30726-9","volume":"22","author":"MM Syeda","year":"2021","unstructured":"Syeda, M. M. et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 22, 370\u2013380 (2021).","journal-title":"Lancet Oncol."},{"key":"72735_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.  Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"72735_CR23","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1073\/pnas.1508074112","volume":"112","author":"JZ Sanborn","year":"2015","unstructured":"Sanborn, J. Z. et al. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc. Natl. Acad. Sci. USA 112, 10995\u201311000 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"72735_CR24","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain, A. H. et al. The genetic evolution of melanoma from precursor lesions. N. Engl. J. Med. 373, 1926\u20131936 (2015).","journal-title":"N. Engl. J. Med."},{"key":"72735_CR25","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1080\/21645515.2019.1696075","volume":"16","author":"M Gonzalez-Aparicio","year":"2019","unstructured":"Gonzalez-Aparicio, M. & Alfaro, C. Significance of the IL-8 pathway for immunotherapy. Hum. Vaccines Immunother. 16, 2312 (2019).","journal-title":"Hum. Vaccines Immunother."},{"key":"72735_CR26","doi-asserted-by":"publisher","first-page":"e000842","DOI":"10.1136\/jitc-2020-000842","volume":"8","author":"AS Laino","year":"2020","unstructured":"Laino, A. S. et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J. Immunother. Cancer 8, e000842 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"72735_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025318","volume":"100","author":"J Xu","year":"2021","unstructured":"Xu, J., Zhao, J., Wang, J., Sun, C. & Zhu, X. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1\/PD-L1 therapy: a meta-analysis. Medicine 100, e25318 (2021).","journal-title":"Medicine"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72735-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72735-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72735-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:52:16Z","timestamp":1784674336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72735-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72735"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72735-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.S.: Speaker fee MSD, Merck, Eisai, Immunocore, Regeneron, BMS, DSM for CDR-Life, Advisory for Regeneron\/Sanofi, Advisory for MSD, DSM for Immunocore. F.M.: Co-inventor on patents related to cell-free DNA analysis. Consulted for Roche Dx. Received material support from Biomodal. R.P.: In the last 3 years, received Honoraria for attending advisory boards from Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa Benevolent AI and Sanofi Aventis. Received honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, and AstraZeneca. Paid for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer, MSD and BMS. Received funds to support attendance at conferences from MSD and BMS. S.T.: Speaking fees from Roche, AstraZeneca, Novartis and Ipsen. Has the following patents filed: Indel mutations as a therapeutic target and predictive biomarker, and PCTGB2018\/051893 and Clear Cell Renal Cell Carcinoma Biomarkers P113326GB. R.M.: Founder, COO, Director and share holder in Oncodrug Ltd; Founder, CEO and share holder in MyT Bioscience Ltd. C.D.: Research funding\/educational research grants: Amgen, AstraZeneca, Astex Pharmaceuticals, Angle PLC, Boehringer Ingelheim, Biomodal, Carrick Therapeutics, Celgene, Clearbridge Biomedics, Epigene Therapeutics Inc, Guardant, Menarini, Merck AG, Neomed Therapeutics, Taiho Oncology, Thermo Fisher Scientific, UCB Pharma, RedX Pharma and CV6 Therapeutics (NI) Ltd. Honoraria for consultancy and\/or advisory boards: Merck, AstraZeneca, GRAIL, Boehringer Ingelheim, VHIO, CIC bioGUNE, The Centre for Discovery in Cancer Research (CDCR). Personal: IFOM. PL Consultant and speakers bureau: BMS, MSD, Pierre Fabre, Novartis, Amgen, Roche, Melagenix, Skyline, MLA Diagnostics. Research funding: BMS, Pierre Fabre. Support for travel: BMS, MSD. Advisory Board Lovance. R.L.: Consultant and speakers bureau: MSD, Pierre Fabre. Research funding: BMS, Pierre Fabre, AstraZeneca. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6850"}}